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Introduction
Since the successful and wide use of the anti-HER2 humanized monoclonal antibody, trastuzumab, for treatment of breast cancers, many therapeutic approaches using inhibitors against target molecules in various cancers have actually been in clinical use. Molecular targeted therapy is mainly composed of (1) humanized monoclonal antibodies or (2) small molecule tyrosine kinase inhibitors (TKIs). Current clinically available molecular targeted therapy is listed in
EGFR (EGFR1)
EGFR is another transmembrane protein that belongs to the EGFR family. In lung cancers, the mutations at exons 20 and 22 are associated with a positive response to Gefitinib, . PCR followed by direct DNA sequencing and FISH are the 
c-kit (CD117)
KIT is a transmembrane protein which is also related to TKs. Diagnosis of GIST is made based on the combination of morphology and immunohistochemical positivity for CD34, Imatinib,  is often used to treat GIST and the GIST patients with mutations on exon 11 respond better to Imatinib. However, mutation on exon 9 is often associated with duodenal GISTs and a poor response to Imatinib, which frequently contributes to a worse outcome [14] [15] [16] .
Bcr/abl
The translocation of bcr/abl is related to activation of TKs in CML, which can be treated with TKIs such as Imatinib and more recently Nilotinib [17] .
Multiple TKIs
The tumours which are activated by multiple TKs and the Imatinibresistant GISTs with secondary mutations may respond better to the drugs which inhibit multiple TKs, such as Soratinib and Sunitinib. Currently, these multi-targeted TKIs are being used for the treatment of RCC, while Lapatinib, which inhibits both HER2-related TKI and EGFR-related TKI, has been used against Trastuzumab-resistant breast cancers [18, 19] . [23] [24] [25] [26] . 
AKT/mTOR
Somatostatin receptors
Somatostatin receptors (SSTRs) are composed of five subtypes, SSTR1, 2a, 3, 4 and 5. These (Fig. 2) .
Summary
This introduction for the series of the MTCT series is designed to give an overview of the current direction of this field and outlines the roles of pathologists in determining the target molecules for the most appropriate management of patient care.
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